Publication | Closed Access

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

OncologyGastrointestinal OncologyMolecular TargetMedicinePathologySti-571 Glivec®Molecular OncologyCancer TreatmentCancer BiologyRadiation OncologyCancer ResearchImatinib MesylateTumor Biology